Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | PNLIP | P16233 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913097 | 0.86 | LMNA (0.66) | LMNATP53HTTNPC1RAB9A | |
| SCHEMBL13523838 | 0.86 | LMNA (0.63) | LMNATP53HTTNPC1RAB9A | |
| SCHEMBL8405384 | 0.84 | LMNA (0.69) | LMNATP53HTTNPC1RAB9A | |
| SCHEMBL18327174 | 0.80 | LMNA (0.89) | LMNATP53HTTNPC1RAB9A | |
| SCHEMBL5079177 | 0.76 | RAB9A (1.00) | LMNATP53HTTNPC1RAB9A | |
| Osalmid SCHEMBL29928981 | 0.75 | LMNA (1.00) | LMNATP53HTTNPC1RAB9A | |
| Osalmid SCHEMBL220088 | 0.75 | LMNA (1.00) | LMNATP53HTTNPC1RAB9A | |
| Salicylanilide SCHEMBL14051034 | 0.75 | MEN1 (1.00) | LMNATP53HTTNPC1RAB9A | |
| Salicylanilide SCHEMBL20165864 | 0.75 | MEN1 (1.00) | LMNATP53HTTNPC1RAB9A | |
| Salicylanilide SCHEMBL152221 | 0.75 | MEN1 (1.00) | LMNATP53HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100522-B1 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-1696960-B1 | INTRANASAL ADMINISTRATION OF GLUCOSE-REGULATING PEPTIDES | AMYLIN PHARMACEUTICALS INC (US) | 2010-09-08 | — | — | EP | disclosed |
| US-7309698-B2 | Compositions for delivering bisphosphonates | EMISPHERE TECHNOLOGIES, INC. (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070197437-A1 | COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070161563-A1 | A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-07-12 | — | — | US | disclosed |
| US-7229966-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070129299-A1 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-06-07 | — | — | US | disclosed |
| US-7186691-B2 | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157426-B2 | such as peptide YY, Neuropeptide Y, or Pancreatic polypeptide with solubilizing agent (cyclodextran), chelating agent (ethylenediamine tetraacetic acid), and polyol such as sucrose | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1715885-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | Nastech Pharmaceutical Company Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20030225300-A1 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. | 2003-12-04 | — | — | US | disclosed |
| US-6642411-B1 | Salt of 2-(4-(N-salicyloyl)aminophenyl)propionic acid | EMISPHERE TECHNOLOGIES, INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030072740-A1 | Pulmonary delivery of active agents | EMISPHERE TECHNOLOGIES, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1100522-A4 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6440929-B1 | ACYLATED AMINO ACID OR A SULFONATED AMINO ACID | EMISPHERE TECHNOLOGIES, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1100771-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1100522-A1 | PULMONARY DELIVERY OF ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006534-A9 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000006534-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006184-A1 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072740-A1 | Pulmonary delivery of active agents | ANXA11, ANXA1, PIGS | F10 1076/4885LMNA 1649/4885TP53 3633/4885 |
| US-20030225300-A1 | Compounds and compositions for delivering active agents | ABCB4, ABCB7, ALPP | F10 2614/4885LMNA 485/4885TP53 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.